Introduction
Deep venous thrombosis or DVT is a blood clot formation in one or more of the deep veins. The blood clot does not break down and therefore, it can become larger and occlude the blood flow within the affected vein. The most frequent sites are the leg veins (femoral and popliteal) and the deep pelvic veins. Rarely, the arm veins are affected (Paget-Schrötter disease). Pulmonary embolism (PE) is the most dangerous complication of DVT. PE occurs when the clot breaks into small pieces (emboli) and travel to the lung. The embolus may travel to other vital organs and cause life-threatening complications such as stroke or heart attack.
The etiology of thrombosis is exactly unknown, however, the Virchow's triad of slow circulation (stasis), increased blood coagulability and vessel wall intimal injury is the alleged mechanism.
DVT and PE developing after trauma and pelvic surgery are of a major concern to surgeons of all subspecialties. Therefore, proper assessment of the patient risk to develop DVT is of paramount importance. The risk of DVT can be decreased significantly by adopting some appropriate prophylactic procedures.
Although adopting anti-DVT prophylactic measures is not debatable, the use of these measures has not yet been a universal issue, even in patients having no contraindications to their use.
In this chapter, the term "radical pelvic surgeries" mean all types of major surgeries performed to treat malignancies developing in the pelvis, such as radical cystectomy, salvage cystectomy, radical prostatectomy, radical or pan-hysterectomy, radical surgery for colo-rectal cancer and excision of a local tumor recurrence after primary radical surgery or after definitive radiotherapy over years (Silverstein et al., 1998) . However, the incidence of DVT and PE may be underestimated because of the missed diagnosis, absence of pertinent symptoms or the absence of laws to permit routine autopsies in sudden post-operative mortalities in most centers (Dalen & Alpert, 1975; Clagett, 1994) . Furthermore, unexplained DVT may be the first presentation in some malignancies, such as prostate, colorectal and bladder (Monreal & Prandoni, 1999) .
In a series of 2373 patients, the incidence of DVT was 0.87% after urologic surgeries for prostate and bladder tumors, 2.8% in general surgery and 2% in gynecological surgeries (Scarpa etal., 2007) .
The incidence of DVT may be as low 2% after radical cystectomy (Ali-El-Dein et al., 2008; Ghoneim et al., 2008) , or as high as 40% following prolonged gynecological or obstetrical surgery (Walsh et al., 1974; Clarke-Pearson et al., 1983) . Patients undergoing large bowel surgery also have a considerable risk of DVT and pulmonary embolism. The incidence of DVT following radical cystectomy in our hospital is 2% to 2.6% and PE following DVT or without prior DVT has long been a leading cause of post-operative death (Ali-El-Dein et al., 2008; Ghoneim et al., 2008) . In patients undergoing surgery or radiotherapy for treatment of localized prostate cancer the incidence of DVT was 2% for pelvic lymphadenectomy alone and 1.9% following prostatectomy, while fatal PE occurred in 2 patients (3.7%) after prostatectomy (Bratt et al., 1994) .
The incidence of DVT after gynecologic and obstetrical surgeries varies according to the presence or absence of the known risk factors among patients and according to the methods of diagnosis. It has been reported that this incidence is 14% after benign gynecological surgeries (Walsh et al., 1974) , while the rate has been higher (38%) for patients undergoing surgery for gynecological tumors (Crandon & Knotts, 1983) . In addition, among all causes of death following gynecologic surgeries, PE has been a leading cause of postoperative mortality in high risk women with gynecologic malignancy (Clarke-Pearson et al., 1983) . Following laparoscopic radical hysterectomy for cervical carcinoma the incidence of DVT has been 3% (Chen et al., 2008) .
In the study of yang et al. on 3645 patients undergoing surgery for colorectal cancer, 31 (0.85%) developed symptomatic venous thromboembolism or VTE (Yang et al., 2011) .
Pathogenesis and risk factors
The traditional Virchow's triad of hypercoagulability, Stasis of the venous stream and vessel wall (endothelial) trauma is still the basis of description of the pathophysiology of DVT.
One or more of these three factors may explain DVT in patients with radical pelvic surgeries. The risk factors and the underlying pathogenetic mechanisms of DVT are shown in table (1).
A major factor is immobilization (prolonged bed rest), which can impair venous drainage from the lower limb with subsequent venous stasis (Clark & Cotton, 1968 Endothelial injury of the vessel wall may be induced by surgical dissection in various radical pelvic surgeries (e.g. radical cystectomy) or from infiltration of the vessel wall by the tumor. In addition, catheters placed distally or proximally in the venous system are among the risk factors (Evans et al., 2010) . However, in this situation, the risk of DVT/PE is determined by multiple factors including catheter size (Evans et al., 2010) , degree of vein trauma during catheter insertion and dwell and hypercoagulability of the patient' blood.
Hypercoagulability or thrombophilia or prothrombotic state is a blood coagulation disorder with a subsequent increase in the incidence of thrombosis (Heit, 2007) . There are multiple genetic and acquired risk factors that influence thrombophilia. The presence of these inherited risk factors alone usually does not cause thrombosis unless an additional risk factor is present (Heit, 2007; Kyrle et al., 2010) .
Antithrombin deficiency, which is the first major form of thrombophilia, was identified in 1965, while the most common defects, such as factor V Leiden mutation and prothrombin gene mutation G20210A were described in the 1990s (Dahlbäck, 2008; Rosendaal & Reitsma, 2009 ). The risk of developing DVT/PE increases significantly if one of these abnormalities is present in patients undergoing radical pelvic surgery.
There are various possibilities, which can induce a hypercoagulable state during major radical pelvic surgeries. These possibilities include decreased fibrinolytic activity associated with surgery (Egan et al., 1974) , increased level of coagulation factors I, V, VIII, IX, X, and XI, the presence of activated intermediate coagulation products such as thrombinantithrombin III complexes and abnormalities of the platelets (Piccioli et al., 1996) . In addition, the malignant cells may secrete a substance promoting coagulation, such as tissue factor and cancer procoagulant or factors that influence vascular endothelial permeability such as vascular endothelial growth factor and subsequently stimulate fibrin deposition (Goad & Gralnick, 1996) .
In the prospective study of Duke University Medical Center 411 patients undergoing major abdominal and pelvic gynecologic surgery were evaluated for DVT and the related possible risk factors (Clarke-Pearson et al., 1987) . In this study, the important factors, which maintained statistical significance in stepwise logistic regression model were age, edema of the ankle, type of surgery, nonwhite race, presence of varicose veins, history of radiation preoperatively, past DVT and duration of surgery.
It has been found that the risk factors for distal DVT are different from those of proximal DVT. In the national (France) multicenter prospective OPTIMEV study, out of 6141 patients with symptoms suggestive of DVT, diagnosis was objectively confirmed in only 1643 and isolated distal DVT was more common than proximal one (Galanaud et al., 2009) . In this study, acute or transient risk factors, such as recent surgery, recent plaster immobilization and recent travel, were more frequently discovered in distal DVT. On the other hand, in proximal DVT chronic risk factors such as active cancer, congestive heart failure or respiratory insufficiency and age above 75 years were more frequent.
Active cancer and related chemotherapy can increase the incidence of DVT by multiple mechanisms. In chronic lymphocytic leukemia patients, studies showed a link between lenalidomide associated DVTs and inflammation, upregulation of TNFα and endothelial cell dysfunction (Aue etal., 2011) .
Diagnosis of DVT/PE
The majority of cases of DVT/PE have one or more risk factor. Many cases of DVT/PE are asymptomatic. Suspected pulmonary embolism is a medical emergency and can be fatal. In symptomatic DVT cases, the patient may present with lower limb pain, unilateral leg swelling, redness and sometimes prominent superficial veins. A tender calf, especially with dorsiflexion (Homan's sign) and rarely a palpable venous cord are among the possible physical signs. However, the presence of these manifestations is nonspecific, because in more than 50% of the cases presenting with these symptoms, DVT is absent (Dainty et al., 2004) . Therefore, diagnosis of DVT based on symptoms only is problematic and proper hospital assessment and further diagnostic tools are needed for accurate diagnosis. Similarly, most of the symptoms and signs of PE are nonspecific and simulate post-surgery pulmonary complications. However, physicians should maintain a high degree of suspicion if the patient is complaining of pleuritic chest pain, hemoptysis, dyspnea, tachycardia and tachypnea.
Laboratory testing
The use of a simple prediction tool, together with the laboratory tests of D-dimers and arterial blood gases (ABG) in cases of suspected PE are useful tools to exclude or prove DVT (Crisan et al., 2011) . D-dimers are fibrinogen degradation products which are generally present at higher concentrations than normal in the blood of people with DVT.
Imaging in DVT
Imaging for DVT includes B-mode duplex Doppler ultrasound, impedance plethysmography, contrast venography, and magnetic resonance venography (MRV). Doppler ultrasound is currently the most common technique for the diagnosis of symptomatic DVT. B-mode ultrasonography allows a bi-dimensional image of the vessels of the lower extremity and when compression techniques are used, a sensitivity of up to 90% and a specificity of 96% to 100% can be achieved in the detection of DVT (Cronan et al., 1987; O'Leary et al., 1988) .
In duplex ultrasonography B-mode is combined with Doppler flow, therefore, providing information about flow velocity. When color Doppler flow is used with compression Bmode ultrasonography (color duplex ultrasonography), additional data on the direction of flow is gained (Cronan et al., 1987; O'Leary et al., 1988) .
Impedance plethysmography is a noninvasive diagnostic test that has a good accuracy in the detection of proximal DVT, when the results are analyzed in combination with positive clinical data (Kearon et al., 1998) . However, false positive results may be obtained with this test and if the results of this test are non-diagnostic or not coping with the clinical data, venography should be performed (Kearon et al., 1998) .
Contrast venography is still the gold standard for the diagnosis of DVT and is used by investigators as a reference standard for testing the new noninvasive diagnostic DVT measures (Tapson et al., 1999) .
The technique is done as classically described (Rabinov & Paulin, 1972) . A misdiagnosis is expected if all the deep veins from the leg up to the vena cava are not seen. When there is a persistent filling defect in the lumen of 2 or more veins, the diagnosis of DVT is confirmed (Rabinov & Paulin, 1972) . Currently, contrast venography is rarely indicated nowadays and has been replaced by the noninvasive measures. It is sometimes performed to confirm the diagnosis of a clinically suspected DVT. However, if noninvasive imaging is normal or inconclusive and still DVT is clinically suspected, venography is done to confirm the diagnosis. In the cases of clinical suspicion of DVT, a negative contrast venography rules out the need for anticoagulant treatment (Hull et al., 1981) . The test has certain limitations and complications.
Magnetic resonance venography (MRV) is an accurate noninvasive venographic technique for the detection of DVT. It has a sensitivity and specificity comparable to contrast venography (Carpenter et al., 1993) . Furthermore, it can detect thrombi places not seen by the conventional venography, such as pelvic, ovarian veins or vena cava. Two major limitations for MRV are present, namely, the expensive cost and prolonged time necessary (Carpenter et al., 1993 ).
Scintigraphy has been described as a diagnostic tool for DVT (Knight, 1993) . However, the data of its clinical efficacy compared to the standard methods are still lacking.
Imaging in PE
The diagnosis of PE may be made by a variety of imaging techniques, including chest X-ray, ventilation-perfusion scan, computed tomography (CT) of the chest vessels and pulmonary angiography.
On clinical suspicion of PE, the initial evaluation is made using chest X-ray, Electrocardiography (ECG) and ABG. Further evaluation is made by ventilation-perfusion scan, CT of the chest vessels (Gulsun Akpinar & Goodman, 2008) .
Currently, CT venography combined with pulmonary CT angiography for the detection of PE is increasingly used to confirm the diagnosis of suspected PE and the results have been extremely promising (Krishan et al., 2011) .
Prophylaxis of DVT/PE
The incidence of DVT and subsequent PE can be decreased by adopting certain prophylactic mechanical and/ or pharmacologic measures, which have been proved to be safe and effective in most types of major surgeries (Martino et al., 2007; Geerts et al., 2008) . Mechanical methods act by reducing stasis of venous blood and may stimulate endogenous fibrinolysis, while pharmacologic agents act by clot prevention through the various steps of the clotting cascade (Martino et al., 2007; Geerts et al., 2008) .
Mechanical measures
Mechanical prophylaxis is usually simple to conduct and relatively less costy. It may be achieved through the use of graduated compression stockings, anti-embolism stocking, electrical stimulation of the leg muscles, intermittent external pneumatic calf compression and/ or the use of specific tables (Martino et al., 2007; Geerts et al., 2008; Miller, 2011) .
Pharmacologic measures
These measures are very effective in most surgeries and therefore, should be made a routine practice (Agnelli, 2004) . Low-dose unfractionated heparin or low-molecular-weight heparin (LMWH) are the drugs of choice in patients undergoing radical pelvic operations in the fileds of general, vascular, major urologic and gynecologic surgeries (Agnelli, 2004) . In urologic patients judged as low-risk, early postoperative mobilization is the only measure needed. On the other hand, higher-risk patients should receive vitamin K antagonists, LMWH and/ or fondaparinux (Agnelli, 2004) .
Some investigators recommended a double prophylaxis of mechanical measures as well as pharmacologic measures using pre-and post-operative anticoagulation, usually in the form of LMWH (Whitworthet al., 2011) . They found that the use of preoperative anticoagulation seems to significantly decrease the risk of DVT in high-risk patients undergoing major gynecologic surgeries. In addition, there was no significant change in the rates of complications secondary to this protocol.
Dual prophylaxis
DVT may develop while the patient is on prophylaxis, therefore, the idea of dual prophylaxis (mechanical and pharmacologic) has emerged (Dainty et al., 2004; Whitworthet al., 2011) .
This combination has been evaluated in patients undergoing colorectal operations. A combination of low-dose unfractionated heparin and graduated compression stockings has been found to be 4-fold more effective than low-dose unfractionated heparin alone in DVT/PE prophylaxis (Wille-Jorgensen et al., 2003) . Similarly, this dual prophylaxis has been found to be cost-effective in high-risk patients undergoing surgeries for gynecologic tumors (Dainty et al., 2004) .
Duration of prophylaxis during radical pelvic surgeries
Following radical pelvic surgery, mechanical prophylaxis may be started before the operation, while pharmacologic prophylaxis is usually started after the operation and continued daily for 5-10 days or until the patient was fully mobile (Geerts et al., 2008;  unpublished data by the author).
Treatment of DVT/PE
The goals of treatment of patients with DVT and PE are to prevent local growth of the thrombus, prevent the thrombus from breaking down into small pieces (emboli) and traveling to other places, prevent complications of DVT, prevent recurrence of the thrombus and in some clinical situations accelerate fibrinolysis (Hirsh & Hoak, 1996) .
DVT is treated by immediate institution of anticoagulant therapy. Treatment is given as either unfractionated heparin or low molecular weight heparins, followed by few weeks to 6 months of oral anticoagulant therapy (Clarke-Pearson & Abaid, 2008) . However, life-long anticoagulation has been recommended in some patients with active cancers after partial improvement or failure of treatment, because they remain at very high risk to recurrent DVT (Clarke-Pearson & Abaid, 2008) .Low concentrations of heparin can inhibit the early stages of blood coagulation. However, higher concentrations are needed to inhibit the much higher concentrations of thrombin that are formed if the DVT process is not modulated (Hirsh & Hoak, 1996) .
When unfractionated heparin is used, we usually start by a bolus injection followed by continuos infusion and the dose is then adjusted to maintain the level of activated partial thromboplastin time (APTT) at 1.5-2.5 times the control value (Clarke-Pearson & Abaid, 2008) . Oral anticoagulation (warfarin) should be started on the first day of the heparin infusion aiming to achieve an international normalized ratio (INR) of 2.0-3.0. IV heparin may be discontinued in 5 days if an adequate INR level has been established (ClarkePearson & Abaid, 2008) . Studies have demonstrated that some of the new anticoagulants, such as hirudin and its fragments, are effective inhibitors of clot-bound thrombin and therefore, they may provide a better efficacy than heparin in neutralizing the procoagulant effects of the fibrin-bound thrombin (Weitz et al., 1990 ).
Low molecular weight heparins such as enoxaparin and dalteparin have been proved to be as effective and safe as unfactionated heparin in the treatment and recurrence prophylaxis of DVT/PE (Quinlan et al., 2004) . They have the advantage of the possibility to be given in the outpatient setting (Clarke-Pearson & Abaid, 2008) .
Fibrinolysis can be performed by one of the fibrinolytic enzymes, such as streptokinase, urokinase and TPA, all of them can increase the dissolution rate of the thromus or embolus (Hirsh & Hoak, 1996) . They are not routinely recommended in the treatment of DVT/PE, because of their cost and the high risk of bleeding (Hirsh & Hoak, 1996) . Thrombolytic therapy is indicated in all patients with massive pulmonary embolism and in some selected cases of proximal DVT or with severe obstruction (Hirsh & Hoak, 1996) . Thrombolytic therapy has the advantage of preserving the pulmonary microcirculation after PE and decreasing the possibility of post-thrombotic syndrome (PTS) following DVT (Linn et al., 1988) . Intrapulmonary artery infusion of urokinase in extensive PE has been found to be safe and effective in treatment of patients with and without contraindication to the use of systemic thrombolytic therapy (McCotter et al., 1999) . With the recommended dose, thrombolytic therapy produces significant and rapid resolution of pulmonary emboli with a low morbidity and mortality rate. However, in lower extremity DVT, therapeutic thrombolysis is still controversial.
In PE immediate anticoagulant therapy is given and respiratory support is maintained. In addition, pulmonary artery catheterization with the administration of thrombolytic agents has been tried as previously mentioned (McCotter et al., 1999) .
Surgical intervention of the thrombus or embolus is rarely indicated. However, surgical extirpation of the thrombus (venous thrombectomy), of the embolus (pulmonary embolectomy) and endovascular therapies to treat DVT have been reported with promising results (Lindow et al., 2010; Jenkins, 2011) .
Long-term results after transfemoral venous thrombectomy for iliofemoral DVT has shown that the technique is safe and effective and can prevent the development of severe postthrombotic syndrome in the long term (Lindow et al., 2010) .
Inferior vena cava filters have been introduced to prevent PE in patients in whom anticoagulation therapy is contraindicated, has failed or has been associated with complications and in patients with extensive free-floating thrombi or residual thrombi following massive PE (Chung et al., 2008; Kalva et al., 2008) .
Conclusion
Deep venous thrombosis and pulmonary embolism are among the major post-operative complications that develop after radical pelvic surgeries. Pulmonary embolism is one of the leading causes of post-operative mortality in these patients. Most of the cases are asymptomatic and in the majority of patients dying from pulmonary embolism the embolism is diagnosed at autopsy. Treatment is essentially prophylactic and the primary treatment objectives are to prevent PE, decrease morbidity and to prevent the risk of developing the post-thrombotic syndrome (PTS). High-risk patients may be subject for dual mechanical and pharmacologic prophylaxis with good results. Anticoagulation provides the main stay of treatment. Thrombolytic therapy is currently used for massive pulmonary embolism and some selected cases of deep venous thrombosis. Surgical (thrombectomy or embolectomy) or endovascular techniques have been tried with promising results.
